09th Nov 2020 – Neurelis, Inc.
issued an announcement, which is summarized as follows：
Neurelis, Inc., announced today that the company’s
lead product, VALTOCO® (diazepam nasal spray), is now available through
pharmacies nationwide. VALTOCO was approved by the FDA earlier this year for
the acute treatment of intermittent, stereotypic episodes of frequent seizure
activity (ie, seizure clusters, acute repetitive seizures) that are distinct
from a patient’s usual seizure pattern in adult and pediatric patients 6 years
of age and older. At the time of approval, the FDA also granted VALTOCO 7 years
of Orphan Drug Exclusivity. The FDA recognized VALTOCO’s intranasal route of
administration as clinically superior to the previously approved
standard-of-care treatment (a rectal gel formulation of diazepam) as the basis
for granting Orphan Drug Exclusivity.
Initially, VALTOCO was made available
exclusively through Maxor Specialty Pharmacy. “Our goal has been to
consistently provide broad and reliable access to VALTOCO for patients in the
epilepsy community who may benefit from this important medication,” said
Craig Chambliss, the company’s President and Chief Executive Officer.
“Seizure episodes can happen at any time and any place. Patients, care
partners, and healthcare providers need a reliable product that is available
when and where they need it.”
Chuck DeWildt, Chief Commercial Officer at
Neurelis, added, “VALTOCO’s availability through retail chains and
independent pharmacies will now allow patients to pick up their prescriptions
at their preferred outlet, including health system pharmacies and institutional
pharmacies. Hospitals, outpatient clinics, and long-term care facilities can
now also stock VALTOCO. Our mission is to make access to VALTOCO as simple as
possible for people living with epilepsy and their families. VALTOCO will also
continue to be available through Maxor Specialty Pharmacy for customers who
prefer to use Maxor for a specialty pharmacy experience.”
DeWildt said Neurelis will continue to offer
patient assistance programs in the form of copay assistance for commercial
patients (through which eligible patients could pay as little as $20 for a
prescription) and a patient assistance program in which eligible patients who
do not have insurance may qualify for additional assistance. “These programs
have taken on added importance because of the COVID-19 pandemic and we remain
committed to providing access to anyone who is prescribed VALTOCO,”
DeWildt said. For additional information, people are urged to visit
www.valtoco.com or contact myNEURELIS? at 866.696.3873 or by visiting
www.myNEURELIS.com. myNEURELIS provides individualized support for VALTOCO
patients, including access to nurse educators, insurance coverage checks,
financial assistance for those who need it, and more.
The original website link：
https://www.neurelis.com/neurelis-news/neurelis-announces-national-wholesale